15 Jul 2026
Sun Pharma received approval to manufacture and market generic semaglutide in South Africa.
The product will be launched as a pre-filled multi-dose injectable pen. South Africa is one of the first markets where semaglutide loses patent protection, which makes it an early test of how quickly Indian manufacturers convert the GLP-1 opportunity into shipped product rather than a filing. The approval gives Sun a route to market ahead of the larger patent expiries still to come.